FTC Backs J&J's FTC Synthes Acquisition in Light of Conditional Biomet Deal

, The Am Law Daily

   | 0 Comments

In a move that removes an obstacle to its proposed $21.3 billion acquisition of Synthes, Johnson & Johnson has agreed to sell its global trauma business to Biomet Inc. for $280 million. Weil is serving as antitrust counsel to J&J, while Cravath is serving as deal counsel on both transactions. Cleary is advising Biomet.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Continue to Lexis Advance®

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202559187848

Thank you!

This article's comments will be reviewed.